• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >β-Lactamase inhibitor peptides as the new strategies to overcome bacterial resistance.
【24h】

β-Lactamase inhibitor peptides as the new strategies to overcome bacterial resistance.

机译：β-内酰胺酶抑制剂作为克服细菌抗性的新策略。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Bacterial resistance has become a problem of great concern all over the world. Gram-negative bacteria, including the Enterobacteriaceae family and Pseudomonas and Acinetobacter species, are among the leading causes of healthcare-associated infections. The rate of antibiotic resistance among these pathogens has increased dramatically in recent years, reaching a pandemic scale. The most common mechanism of resistance described for Gram-negative bacteria consists of beta-lactamase production. These enzymes hydrolyze beta-lactam antibiotics, which are among the most commonly used antimicrobial agents. As with other antibiotics, reports of bacterial resistance to these agents have increased in recent years. An alternative method for combating beta-lactamasemediated resistance has been the use of small beta-lactamase inhibitors (e.g., clavulanic acid and tazobactam), allowing the resurgence of beta-lactam antibiotics for the treatment of infections caused by beta-lactamase-producing bacteria. However, due to the beta-lactamase group's diversity, some of them present resistance to conventional beta-lactamase inhibitors. Bearing this in mind, in the last two decades, beta- lactamase inhibitor peptides have been developed as alternative adjuvants to strike back against such strains. In this review, we outline the most recent findings related to the design of beta-lactamase inhibitor peptides and their biotechnological potential.
机译：细菌抗性已成为世界各地令人震惊的问题。革兰氏阴性细菌，包括肠杆菌痤疮家族和假单胞菌和致癌物种，是医疗保健相关感染的主要原因。近年来，这些病原体之间的抗生素抗性率急剧增加，达到了大流行量表。对革兰氏阴性细菌描述的最常见的抗性机制包括β-内酰胺酶生产。这些酶水解β-内酰胺抗生素，这些抗生素是最常用的抗微生物剂。与其他抗生素一样，近年来对这些药物的细菌抗性的报道增加。用于打击β-乳酸缺血性耐药性的替代方法已经使用了小β-内酰胺酶抑制剂（例如，克拉维酸和塔唑酰胺），从而允许β-内酰胺抗生素的复苏治疗由β-内酰胺酶产生的细菌引起的感染。然而，由于β-内酰胺酶组的多样性，其中一些存在对常规β-内酰胺酶抑制剂的抗性。在过去的二十年中，介于这一点，已经开发了β-内酰胺酶抑制肽作为替代佐剂，以反对这种菌株。在本综述中，我们概述了与β-内酰胺酶抑制剂肽的设计有关的最新发现及其生物技术潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号